Teva Submits $125M Bid for BioXcel Assets in Bankruptcy Auction
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), has submitted a stalking-horse bid to acquire substantially all assets from BioXcel Therapeutics Inc. (NASDAQ:BTAI) as part of its Chapter 11 bankruptcy process. The proposed deal includes $57.5 million in cash at closing and up to an additional $67.5 million contingent on future milestones, with a total maximum value of $125 million plus assumed liabilities. The assets include IGALMI, the BXCL501 program, and other neuroscience-related properties. Teva is seeking expanded FDA approval for home use of IGALMI to treat acute agitation in schizophrenia or bipolar disorder patients, pending regulatory action by November 14, 2026. The transaction requires court approval under Section 363, which may allow the transfer free from certain debts and liens. While Teva's current ownership position is not guaranteed due to potential competing bids, its existing psychiatric product portfolio aligns well with a possible outpatient expansion of IGALMI’s use. However, regulatory uncertainty remains significant as safety concerns for at-home administration could limit label approval or adoption.
